The Experts below are selected from a list of 789 Experts worldwide ranked by ideXlab platform
Wei Shan Lim - One of the best experts on this subject based on the ideXlab platform.
-
a bilayer swellable drug eluting Ureteric Stent localized drug delivery to treat urothelial diseases
Biomaterials, 2018Co-Authors: Wei Shan Lim, Kenneth Chen, Tsung Wen Chong, Gordon Minru Xiong, William R Birch, Jisheng Pan, Bae Hoon Lee, Abhijit Vijay Salvekar, Subbu S VenkatramanAbstract:A bilayer swellable drug-eluting Ureteric Stent (BSDEUS) is engineered and implemented, as a sustained drug delivery platform technology that enhances localized drug delivery to the highly impermeable urothelium, for the treatment of urothelial diseases such as strictures and carcinomas. On deployment, the device swells to co-apt with the Ureteric wall and ensure drug availability to these tissues. BSDEUS consists of a Stent spray-coated with a polymeric drug containing polylactic acid-co-caprolactone (PLC) layer which is overlaid by a swellable polyethylene glycol diacrylate (PEGDA) based hydrogel. In-vitro quantification of released drug demonstrated a tunable time-profile, indicating sustained delivery over 1-month. The PEGDA hydrogel overlayer enhanced drug release and transport into explanted porcine Ureteric tissues ex-vivo, under a simulated dynamic fluid flow. A preliminary pilot in-vivo feasibility study, in a porcine model, demonstrated that the swollen hydrogel co-apts with the urothelium and thus enables localized drug delivery to the target tissue section. Kidney functions remained unaffected and device did not result in either hydronephrosis or systemic toxicity. This successful engineering of a bilayer coated Stent prototype, demonstrates its feasibility, thus offering a unique solution for drug-based urological therapy.
Subbu S Venkatraman - One of the best experts on this subject based on the ideXlab platform.
-
a bilayer swellable drug eluting Ureteric Stent localized drug delivery to treat urothelial diseases
Biomaterials, 2018Co-Authors: Wei Shan Lim, Kenneth Chen, Tsung Wen Chong, Gordon Minru Xiong, William R Birch, Jisheng Pan, Bae Hoon Lee, Abhijit Vijay Salvekar, Subbu S VenkatramanAbstract:A bilayer swellable drug-eluting Ureteric Stent (BSDEUS) is engineered and implemented, as a sustained drug delivery platform technology that enhances localized drug delivery to the highly impermeable urothelium, for the treatment of urothelial diseases such as strictures and carcinomas. On deployment, the device swells to co-apt with the Ureteric wall and ensure drug availability to these tissues. BSDEUS consists of a Stent spray-coated with a polymeric drug containing polylactic acid-co-caprolactone (PLC) layer which is overlaid by a swellable polyethylene glycol diacrylate (PEGDA) based hydrogel. In-vitro quantification of released drug demonstrated a tunable time-profile, indicating sustained delivery over 1-month. The PEGDA hydrogel overlayer enhanced drug release and transport into explanted porcine Ureteric tissues ex-vivo, under a simulated dynamic fluid flow. A preliminary pilot in-vivo feasibility study, in a porcine model, demonstrated that the swollen hydrogel co-apts with the urothelium and thus enables localized drug delivery to the target tissue section. Kidney functions remained unaffected and device did not result in either hydronephrosis or systemic toxicity. This successful engineering of a bilayer coated Stent prototype, demonstrates its feasibility, thus offering a unique solution for drug-based urological therapy.
Kenneth Chen - One of the best experts on this subject based on the ideXlab platform.
-
a bilayer swellable drug eluting Ureteric Stent localized drug delivery to treat urothelial diseases
Biomaterials, 2018Co-Authors: Wei Shan Lim, Kenneth Chen, Tsung Wen Chong, Gordon Minru Xiong, William R Birch, Jisheng Pan, Bae Hoon Lee, Abhijit Vijay Salvekar, Subbu S VenkatramanAbstract:A bilayer swellable drug-eluting Ureteric Stent (BSDEUS) is engineered and implemented, as a sustained drug delivery platform technology that enhances localized drug delivery to the highly impermeable urothelium, for the treatment of urothelial diseases such as strictures and carcinomas. On deployment, the device swells to co-apt with the Ureteric wall and ensure drug availability to these tissues. BSDEUS consists of a Stent spray-coated with a polymeric drug containing polylactic acid-co-caprolactone (PLC) layer which is overlaid by a swellable polyethylene glycol diacrylate (PEGDA) based hydrogel. In-vitro quantification of released drug demonstrated a tunable time-profile, indicating sustained delivery over 1-month. The PEGDA hydrogel overlayer enhanced drug release and transport into explanted porcine Ureteric tissues ex-vivo, under a simulated dynamic fluid flow. A preliminary pilot in-vivo feasibility study, in a porcine model, demonstrated that the swollen hydrogel co-apts with the urothelium and thus enables localized drug delivery to the target tissue section. Kidney functions remained unaffected and device did not result in either hydronephrosis or systemic toxicity. This successful engineering of a bilayer coated Stent prototype, demonstrates its feasibility, thus offering a unique solution for drug-based urological therapy.
Tsung Wen Chong - One of the best experts on this subject based on the ideXlab platform.
-
a bilayer swellable drug eluting Ureteric Stent localized drug delivery to treat urothelial diseases
Biomaterials, 2018Co-Authors: Wei Shan Lim, Kenneth Chen, Tsung Wen Chong, Gordon Minru Xiong, William R Birch, Jisheng Pan, Bae Hoon Lee, Abhijit Vijay Salvekar, Subbu S VenkatramanAbstract:A bilayer swellable drug-eluting Ureteric Stent (BSDEUS) is engineered and implemented, as a sustained drug delivery platform technology that enhances localized drug delivery to the highly impermeable urothelium, for the treatment of urothelial diseases such as strictures and carcinomas. On deployment, the device swells to co-apt with the Ureteric wall and ensure drug availability to these tissues. BSDEUS consists of a Stent spray-coated with a polymeric drug containing polylactic acid-co-caprolactone (PLC) layer which is overlaid by a swellable polyethylene glycol diacrylate (PEGDA) based hydrogel. In-vitro quantification of released drug demonstrated a tunable time-profile, indicating sustained delivery over 1-month. The PEGDA hydrogel overlayer enhanced drug release and transport into explanted porcine Ureteric tissues ex-vivo, under a simulated dynamic fluid flow. A preliminary pilot in-vivo feasibility study, in a porcine model, demonstrated that the swollen hydrogel co-apts with the urothelium and thus enables localized drug delivery to the target tissue section. Kidney functions remained unaffected and device did not result in either hydronephrosis or systemic toxicity. This successful engineering of a bilayer coated Stent prototype, demonstrates its feasibility, thus offering a unique solution for drug-based urological therapy.
Gordon Minru Xiong - One of the best experts on this subject based on the ideXlab platform.
-
a bilayer swellable drug eluting Ureteric Stent localized drug delivery to treat urothelial diseases
Biomaterials, 2018Co-Authors: Wei Shan Lim, Kenneth Chen, Tsung Wen Chong, Gordon Minru Xiong, William R Birch, Jisheng Pan, Bae Hoon Lee, Abhijit Vijay Salvekar, Subbu S VenkatramanAbstract:A bilayer swellable drug-eluting Ureteric Stent (BSDEUS) is engineered and implemented, as a sustained drug delivery platform technology that enhances localized drug delivery to the highly impermeable urothelium, for the treatment of urothelial diseases such as strictures and carcinomas. On deployment, the device swells to co-apt with the Ureteric wall and ensure drug availability to these tissues. BSDEUS consists of a Stent spray-coated with a polymeric drug containing polylactic acid-co-caprolactone (PLC) layer which is overlaid by a swellable polyethylene glycol diacrylate (PEGDA) based hydrogel. In-vitro quantification of released drug demonstrated a tunable time-profile, indicating sustained delivery over 1-month. The PEGDA hydrogel overlayer enhanced drug release and transport into explanted porcine Ureteric tissues ex-vivo, under a simulated dynamic fluid flow. A preliminary pilot in-vivo feasibility study, in a porcine model, demonstrated that the swollen hydrogel co-apts with the urothelium and thus enables localized drug delivery to the target tissue section. Kidney functions remained unaffected and device did not result in either hydronephrosis or systemic toxicity. This successful engineering of a bilayer coated Stent prototype, demonstrates its feasibility, thus offering a unique solution for drug-based urological therapy.
